(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.06% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Merck & Co's revenue in 2025 is $64,235,000,000.On average, 29 Wall Street analysts forecast MRK's revenue for 2025 to be $162,398,734,530,480, with the lowest MRK revenue forecast at $156,402,168,083,504, and the highest MRK revenue forecast at $169,355,843,698,888. On average, 29 Wall Street analysts forecast MRK's revenue for 2026 to be $170,452,897,659,800, with the lowest MRK revenue forecast at $160,341,137,848,136, and the highest MRK revenue forecast at $181,619,517,049,264.
In 2027, MRK is forecast to generate $179,936,705,769,856 in revenue, with the lowest revenue forecast at $168,814,762,786,040 and the highest revenue forecast at $194,997,618,518,304.